Table 4.
Evaluation indexes were used to explicate the ability of four indicators in forecasting PCa.
| Evaluation indexes | PSA | PSAD | MP-MRI | PBRS |
|---|---|---|---|---|
| Youden’s index | 0.04 | 0.25 | 0.32 | 0.57 |
| Likelihood ratio (+) | 12.41 | 135.35 | 179.02 | 356.39 |
| PPV (%) | 533/1034 (52) |
523/904 (58) |
516/854 (60) |
445/586 (76) |
| OR (95%CI) | 3.19 (1.60–6.38) | 10.00 (6.22–16.08) | 10.69 (7.03–16.25) | 12.69 (9.48–16.98) |
| Overall accuracy (%) | 566/1078 (53) |
676/1078 (63) |
712/1078 (66) |
839/1078 (78) |
| AUC (95%CI) for all cancer | 0.75 (0.72–0.78) |
0.79 (0.76–0.81) |
0.80 (0.78–0.83) |
0.87 (0.85–0.89) |
| AUC (95%CI) for Gleason score >=7 | 0.77 (0.74–0.80) |
0.79 (0.77–0.82) |
0.81 (0.79–0.84) |
0.87 (0.85–0.89) |
| AUC (95%CI) for Clinical stage >=T2b | 0.79 (0.76–0.82) |
0.79 (0.77–0.83) |
0.80 (0.77–0.83) |
0.86 (0.84–0.89) |
| AUC (95%CI) for D’Amico risk (>Low) | 0.79 (0.76–0.81) |
0.81 (0.79–0.84) |
0.81 (0.79–0.84) |
0.88 (0.86–0.90) |
Abbreviations: PCa: prostate cancer; PSA: prostate-specific antigen; PSAD: PSA density; MP-MRI: multi-parametric magnetic resonance imaging; CI: confidence interval. PBRS: prostate biopsy rating scale; PPV: positive predictive value; OR: odds ratio; AUC: area under the curve.